Biotech Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) on Tuesday released its operational and financial results for the three and six months ended June 30th, 2018.
Highlights:
- Private placement of 19,306,668 common share units at a price of $0.375 per unit, for gross proceeds of approximately $7,240,000.
- Received proceeds of $1,550,204 related to the exercise of common stock warrants and stock options.
- Announced the initiation of producer cell line development for PMN310, our lead therapeutic antibody candidate for treatment of AD.
More information can be found
here.
The Company was in the news last week when it issued its
commentary on key lessons from this year's Alzheimer's Association International Conference (AAIC 2018). PMN noted that clinical trials indicate that selective targeting of toxic starch-like proteins called amyloid-beta oligomers that are deposited in human tissues is critical for therapeutic efficacy.
FULL DISCLOSURE: ProMIS Neurosciences Inc.is a paid client of Stockhouse Publishing.